The Pharmacist is Pharma Marketing’s Forgotten HCP Stakeholder

This article is part of solli’s October series exploring  HCP and Patient Engagement. 

When did pharma marketing decide that its job ends the moment a prescription is written?  

Somewhere along the way, the industry built an entire discipline—point-of-care media, EHR messaging, physician follow-up—around a single signature, then stopped tracking what happened to that prescription next. That is not a measurement gap. It is a strategic blind spot, and it sits at exactly the point where a written prescription either becomes a filled one or does not. 

Every dollar in point-of-care marketing has, for two decades, pointed at the same moment: the physician’s decision inside the exam room. Waiting room media, in-EHR display, follow-up email, all built to influence what gets written on the script. It is a well-instrumented, heavily measured, closely scrutinized part of the funnel. 

What comes after has never received the same treatment. Once a script leaves the exam room, it enters a pharmacy system that pharma marketing has almost no visibility into and, until recently, no real way to reach. That is a strange gap for an industry so obsessed with precision everywhere else. 

More than a footnote 

The cost of that gap is hard to ignore. A study published in the Journal of Clinical Oncology tracked over 38,000 patients newly prescribed oral cancer therapies and found prescription abandonment climbed from 10 percent when out-of-pocket cost was under $10, to roughly 32 percent between $100 and $500, to nearly half when the cost exceeded $2,000.  

Separately, a peer-reviewed analysis published in Annals of Pharmacotherapy put the broader toll at $528 billion a year in avoidable illness, hospitalization and death tied to medications never taken as prescribed. 

Those are not patients who changed their minds about their diagnosis. They are patients who reached the counter and stopped there, at the one moment in the entire encounter where pharma marketing has historically had nothing to say. 

And cost is not the only consideration at the counter. A pharmacist acts within real constraints there, over generic substitution and formulary-driven alternatives, and those decisions shape which product a patient actually leaves with.  

Whether a brand holds or is exchanged for an alternative is frequently settled here, after the physician has written the script, by a stakeholder the brand has had no way to reach in the moment the decision is made. 

That is not a footnote to the marketing plan. It is a second decision point, made by a second stakeholder, with real commercial consequence, and it has operated almost entirely outside the reach of the brand that spent the budget upstream. 

Closing the loop 

None of this is because pharmacists don’t matter. Every commercial team knows the counter is where a switch happens or doesn’t, where a coupon gets applied or forgotten, where adherence starts or quietly ends.  

The reason pharma marketing hasn’t built for this moment isn’t a lack of will. It’s that the pharmacy management system was never treated as a channel, the way the EHR eventually was. Reaching a pharmacist in workflow, at the point a specific prescription is actually being processed, requires the same kind of direct, permissioned integration that took the industry years to build for physicians. Most of the category simply never built it. 

The result is an industry that can tell you, with increasing precision, what a physician read, clicked and prescribed, and almost nothing about what happened to that decision 20 minutes later, 40 miles away, at a counter with a pharmacist who never saw a single message from the brand. 

Pharma marketing has spent real money and real years getting good at reaching physicians, and rightly so. It has spent almost none reaching the person standing between a written prescription and a filled one—not for lack of trying, but because the pharmacy was never built as a channel the way the EHR eventually was. That imbalance was a reflection of what the infrastructure allowed, not what brands chose to prioritize. 

The infrastructure gap is closing, but the answer is not a pharmacy tactic bolted onto the end of the plan. A counter reached in isolation is just one more disconnected placement, and the disconnection was always the problem.  

What is now becoming possible is the ability to treat the whole encounter, from the waiting room to the fill, as a single connected clinical event on one intent signal, with the pharmacist reached as its final moment rather than as a separate campaign. The brands that adopt that as it arrives will be the first who can say a prescription written became a prescription filled—and mean it. 

For more on HCP and Patient Engagement, click here.

This guest commentary piece was written by Kamya Elawadhi, co-founder and president at Doceree.